ArticleThe Journal of veterinary medical science2026
Effectiveness of gabapentin in combination therapy for phenobarbital-responsive sialadenosis in a Toy Poodle.
Article in The Journal of veterinary medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 9-year-old Toy Poodle presented with sudden hypersalivation, vomiting, and retching unresponsive to symptomatic treatment. One month later, the mandibular salivary glands were enlarged and painful. Additional signs included weight loss, intermittent stiffness and tremors, and a fly-biting behavior, which is atypical for this disease. Magnetic resonance imaging revealed bilateral enlargement of the parotid and mandibular glands. Oral phenobarbital (PB) led to marked improvement, confirming phenobarbital-responsive sialadenosis. Residual hypersalivation and retching almost completely resolved within 24 hr after gabapentin (GBP) addition, with only mild hypersalivation (about 10% of the initial level) remaining. No recurrence was observed during a 3-year follow-up, during which PB (3.6 mg/kg administered orally twice daily [PO BID]) and GBP (15 mg/kg PO BID) were continued at the same doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.